Previous 10 | Next 10 |
5 Penny Stocks To Buy [or Sell] In October 2020 September’s winding down and that means a whole new stable of penny stocks to watch . This past month was definitely wild across the board for small-caps. What began as a slower month has evolved into what we’re famil...
TherapeuticsMD (TXMD) +6.1% PM, believes that the company is on track to meet or exceed Q3 total net revenue consensus of $15.1M.For the ANNOVERA product, orders to wholesalers, retail pharmacies and online distributors across Q3 have increased that are greater than the pa...
-Company believes industry prescription tracking databases are not accurately tracking ANNOVERA ® - -Underlying retail and wholesale demand for ANNOVERA is strong and growing- -Company experiencing record retail and wholesale growth for ANNOVERA- TherapeuticsMD,...
Knight Therapeutics (KHTRF) and TherapeuticsMD (TXMD) announces approval of BIJUVA capsules by Health Canada. Knight and TherapeuticsMD signed a license agreement in July 2018 pursuant to which TherapeuticsMD granted Knight the exclusive Canadian commercialization rights t...
Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of BIJUVA ® (estradiol and progesterone) capsules by Health Canada. In Canada, BIJUVA is indicated for the treatmen...
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in two upcoming virtual investor conferences. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conferences. Detai...
TherapeuticsMD (NASDAQ: TXMD ) announces that, on September 8, the USPTO issued a second patent (No. 10,765,628) covering Annovera (segesterone acetate and ethinyl estradiol vaginal system), its long-lasting reversible contraceptive for women. More news on: TherapeuticsMD, Inc., Health...
New patents expand U.S. patent protection for ANNOVERA TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced patent updates for ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only long-lasting, patient-...
TherapeuticsMD ( TXMD ) has been a blight in my speculative portfolio for nearly two years as the share price continues to deteriorate and investor sentiment hits rock bottom. At first, I was willing to pay a premium and was confident that the company’s impressive product portfolio and ...
Most Popular Penny Stocks On Robinhood Right Now When it comes to penny stocks , Robinhood has become a popular platform to use among new traders. This gamified trading tool allows easy access to the stock market. Today, with so many new events influencing the way investors buy and sell, a mo...
News, Short Squeeze, Breakout and More Instantly...
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...